District Court, D. New Jersey March 17, 2000, CIV. A. 97-6050 (WHW), 98-159(WHW), 98-1412(WHW), 98-1488(WHW) and 98-2827(WHW) (Bristol-Myers Squibb Co. v. Ben Venue Laboratories)

*524

INTRODUCTION and BACKGROUND

WALLS, District Judge.

Plaintiff Bristol-Myers Squibb Company (“Bristol”) moves for summary judgment that U.S. Patent Nos. 5,641,803 (“the ’803 patent”) and 5,670,537 (“the ’537 patent”) are not unenforceable due to inequitable conduct. Defendants and counterclaim-ants, Zenith Goldline Pharmaceuticals, Inc., IVAX Corporation, Baker Norton Pharmaceuticals, Inc.